Tag: SCXN

CERP, SFOR, SCXN & Extended Watchlist

Cereplast, Inc. CERP

Yesterday morning we made sure to give everyone a heads up on the momentum and volume flowing through CERP, and we sincerely hope people were paying attention. The stock had one heck of a trading session, gapping up to at the open, touched a low of .0451 (just above the level we wanted to see hold as support) before trending up steadily to close one tick below the six-cent high of day at .0599. That represents a nifty intraday move of 33%

We’ve also pointed out a few key features on the chart below:

___

Strikeforce Technologies, Inc. SFOR

SFOR was included in yesterday’s extended watchlist, and went on to turn in a great performance. Like CERP, SFOR gapped up in the morning to .003, and closed at its high of day .005 for a 67% rip. It broke a key resistance level at .0048. The next hurdle is at .0054 (100DMA), followed by .0059 and .0063, recent swing highs from last year.

Should the stock fail to make it past those areas of resistance, we will expect a pullback, however, the volume this week has totaled nearly 50M shares, which indicates that there is a chance for us to see the current momentum spill over into next week.

___

Scout Exploration, Inc. SCXN

We’ve had this play on our long-term watchlist; we’ve done a profile, and a video chart in recent months. If you read the profile and watch the previous video, the stock has done everything we wanted it to do. It held support and has reached a new high, and as long as it continues to make higher highs and higher lows, we will remain bullish on SCXN.

We’ve also prepared an updated video chart which you can view by clicking below:


___

Extended Watchlist:
PMCM, SNDY, TTNC, ABIO, OXGN, SUTR

BMSN, CERP, COIN & Extended Watchlist

Bio-Matrix Scientific Group, Inc. BMSN

BMSN is a really good example of why we suggest that our readers keep a working watchlist of all of the stocks we mention, as there are instances when one of our more dated interests crops up with a new development that sends the stock on a ride. Such was the case with BMSN yesterday, as the company released a PR iterating the initiation of clinical trials for the company’s anemia treatment, HemaXellerate. As a result, yesterday’s trading carried the stock as high as .0062.

A week ago today, we mentioned that we’d like to see support hold at .0035 and .0021 to remain bullish on BMSN, which it did, in fact, manage. From the low of .0032 since last Wednesday’s mention, we are up 94% – From the low following our first ever alert (.0003 on Dec. 26th), yesterday’s high represented an unbelievably impressive gain of 1967%

Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia

Clinical Trial to Evaluate “First in Class” Approach to Bone Marrow Failure Diseases

SAN DIEGO, CA, Feb 05, 2013 (MARKETWIRE via COMTEX) — Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company’s HemaXellerate I(TM) stem cell drug in patients with drug-refractory aplastic anemia.
___

Cereplast, Inc. CERP

We first mentioned CERP as a feature on January 24th, at which time we saw a low of .023. On the 25th, it spiked 59% to .0365. This past Friday the stock saw another low of .0182, before running yesterday to a new high at .043, for an added gain of 136%, and bringing our total cumulative gains to 195% in just under two weeks’ time.

With the amount of momentum and volume we’ve seen trade through CERP recently, we definitely want to keep this one high on our watchlists.

Cereplast Provides Shareholder Update on Italian Application Decree & Announces $300,000 in New Revenue

EL SEGUNDO, Calif., Feb 05, 2013 (GLOBE NEWSWIRE via COMTEX) — Cereplast, Inc. (OTCQB:CERP) (the “Company”), a leading manufacturer of proprietary biobased, compostable and sustainable bioplastics, generated approximately $300,000 in new revenue during the last two weeks of January 2013. These orders received are in addition to the $500,000 of new revenue that was announced on January 23, 2013.

___

Converted Organics, Inc. COIN

 COIN appeared on our extended watchlist yesterday, and thus posted a sizable gain, running from .0019-0029, only to close the day at .0025. That gave us a quick chance at up to 53% in intraday gains.
___

As most of you are undoubtedly aware, we first began really zeroing in on cannabis stocks back in October. From our continued reports on the subject this week, we have seen even more gains to add to the already monumental profits that these plays have afforded us. Our running tally of tracked pot stocks totaled 10 at the start of this week. We are all but certain that even more will crop up (no pun intended), as the fervor over this newly expanding market sector continues to intensify.
___

Extended Watchlist:
SFOR, SCXN, CCRY, JOEZ, CNAM, CLSN

BMSN, KERX & Extended Watchlist

Bio-Matrix Scientific Group, Inc. BMSN

BMSN has been a main point of focus for us this year. We first began paying close attention to BMSN towards the end of 2012 when it was trading as low as .0003. Yesterday, the stock had another rockstar performance, reaching new highs and cracking through another major resistance point at .0035 (200DMA).

After the initial surge we saw from .0003-.0024, we wanted to see support hold off of .001. Now that we have hit new highs, we are raising the bar and looking for new support to hold  at .0035, or below that, the 20DMA of .0021. If we can see these areas hold as support, we are going to remain bullish on BMSN.

Over the span of our coverage on BMSN, we have been afforded the opportunity at an accumulation of up to 1400% in possible gains from .0003 to yesterday’s high of .0045

Most Recent News:

SAN DIEGO, CA, Jan 24, 2013 (MARKETWIRE via COMTEX) — Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate(TM) bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. The publication is an overview of the Investigational New Drug (IND) application that the company plans to file for initiating clinical trials.

__

Keryx Biopharmaceuticals, Inc. KERX

KERX earned us a spot in the Penny Stock Rumble on Tuesday, racking up another solid day of gains, and hitting a high of 8.79. That brings our total possible profits to a very respectable 154%

We are going to be monitoring the activity on KERX following yesterday’s announcement regarding the comnpany’s planned $55M public offering.

Yesterday’s News:

NEW YORK, Jan. 29, 2013 /PRNewswire via COMTEX/ — Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) today announced that it has commenced a $55 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering.

__

Extended Watchlist:
SCXN, ITNS, MYRY, SWVI, ONCI, ENTB